Novartis, Biologics, License, Application, Accepted, Kymriah, Tisagenlecleucel, Treatment, Patients, Relapsed, Refractory, Follicular, Lymphoma, European, Medicine, Agency, USFDA, ELARA, Trial, Oncology, Cell, Gene, Acute, Lymphoblastic, Leukemia, NonHodgkin, Lymphoma, Immunocellular, Cancertherapy, Hypogammaglobulinemia, Innovative, Science, Digital, Technologies